Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 10Stomach Neoplasms 5Colonic Neoplasms 5Carcinoma, Hepatocellular 4Rectal Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Biliary Tract Neoplasms 2Vipoma 1Somatostatinoma 1Resected Liver Metastases From Colorectal Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neutropenia 1Neuroendocrine Tumors 1Malignant Tumor of Pancreas Metastatic to Liver 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Insulinoma 1Glucagonoma 1Gestational Trophoblastic Disease 1Gastrinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Diarrhea 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1

Interventions

Oxaliplatin 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Gastrinoma × Leucovorin × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡